Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2025 | Understanding the I-GRAINE registry: bridging knowledge and daily practice in migraine care

Piero Barbanti, MD, PhD, IRCCS San Raffaele Pisana, Rome, Italy, comments on the I-GRAINE study, a prospective multi-center real-life study on patients with migraine in Italy, aiming to bridge the gap between knowledge and daily practice. Prof. Barbanti highlights four key areas of focus: socio-demographic aspects, patient journey, migraine treatments, and healthcare resource use, with the ultimate goal of de-implementation of unnecessary visits and investigations. This interview took place at the 77th American Academy of Neurology (AAN) Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So the I-GRAINE study is a prospective multi-center real-life study carried out among headache centers in Italy and the rationale is to provide big data on migraine. We know very well the migraine mechanism, at least the pain mechanism, we know and we classify very well migraine attacks, but we hardly know who the migraine patient is. And so the I-GRAINE registry is named as favoring implementation science...

So the I-GRAINE study is a prospective multi-center real-life study carried out among headache centers in Italy and the rationale is to provide big data on migraine. We know very well the migraine mechanism, at least the pain mechanism, we know and we classify very well migraine attacks, but we hardly know who the migraine patient is. And so the I-GRAINE registry is named as favoring implementation science. So in bridging the gap between knowledge and what we do in our daily activity. We could say that there are some major points that we are looking at with this study. First one, the socio-demographic aspect of migraine patients in Italy in a prospective manner. The second point, the patient journey. It takes a lot. We calculated on average 19 years since the beginning of migraine and the first visit at a Headache Center. The third point, migraine treatments. Acute treatments, preventive treatments, what’s the opinion of the patient, what is the persistence of the treatment and so on. The fourth point is the healthcare resource use. For favoring implementation science, the registry is aimed at making a sort of de-implementation of useless visits, useless investigations, which may obviously favor a delayed approach to the disorder, misdiagnosis and obviously an improper use of money and healthcare resource use.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Disclosures

Personal fees: Over the last five years has served as consultant, advisory board member, or has received honoraria from Abbvie, Angelini, Assosalute, Bayer, DOC Pharma, Eli-Lilly, Fondazione Ricerca e Salute, Lundbeck, New Penta, Novartis, Organon, Orionpharma, Pfizer, Teva, Viatris, Visufarma, Zambon, and has been the PI in trials sponsored by Abbvie, Alder, , Amgen, Astra-Zeneca; Bioheaven, Chordate, , ElectroCore, Eli-Lilly, GSK, Lundbeck, New Penta, Noema Pharma, Novartis, Pfizer, Teva.